tbuckley/cabot-search huggingface dataset:
1849P Safety and effectiveness of palliative chemotherapy (CTX) for patients (pts) with malignant bowel obstruction (MBO)
Authors: R. Caparica, L. Amorim, P. Amaral, L.F. Uratani, D. Muniz, A. Hendlisz, J. Glasberg, T.K. Takahashi, E. Abdo, D.F. Saragiotto, J. Sabbaga, M. Mak
Journal: Annals of Oncology (2020)
1228P Integrated analysis of gene expression and chromosomal aberrations to determine the global patterns of DNA methylation heterogeneity in the TRACERx lung study
Authors: F. Gimeno-Valiente, K. Chen, E.L. Cadieux, T.B.K. Watkins, O. Chervova, P. Dhami, H. Vaikkinen, A. Feber, J. Demeulemeester, M. Tanic, S. Beck, P. Van Loo, N. Kanu, C. Swanton
Journal: Annals of Oncology (2020)
Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge
Authors: Jie Liu, Jinming Yu, Xue Meng
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
All Children Thrive: Integration of Nutrition and Early Childhood Development
Authors: Maureen M. Black, Angela C.B. Trude, Chessa K. Lutter
Journal: Annual Review of Nutrition (2020)

Building on the successes of child survival, we review the evidence needed to ensure both that children who survive also thrive and that recommendations promote equity, with no child left behind. To illustrate the critical roles played by nutrition and child development, we revise the Conceptual Framework for the Causes of Malnutrition and Death and the Nurturing Care Framework to create the Conceptual Framework of All Children Surviving and Thriving. The revised framework highlights the goals of child growth and development, supported by health, nutrition, learning, responsive caregiving, and security and safety. We review the challenges posed by undernutrition, stunting, micronutrient deficiencies, overweight, and children not reaching their developmental potential. Although integrated nutrition–childhood development interventions have shown promising effects, most have not been implemented at scale. Implementation science that investigates how and why integrated interventions work in real life, along with the acceptability, feasibility, cost, coverage, and sustainability of the interventions, is needed to ensure equity for all children thriving.
671P Prospective assessment of AR splice variant and PSMA detection on circulating tumour cells of mCRPC patients: Preliminary results of PRIMERA trial (NCT04188275)
Authors: G. Francolini, V. Salvestrini, M. Loi, M. Mangoni, B. Detti, P. Pinzani, F. Salvianti, I. Desideri, M. Aquilano, M. Mariotti, P. Garlatti, G. Stocchi, L.P. Ciccone, S. Lucidi, G. Salvatore, M. Sottili, I. Meattini, L. Livi
Journal: Annals of Oncology (2020)
749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
Authors: P. Sharma, A.O. Siefker-Radtke, F. de Braud, U. Basso, E. Calvo, P. Bono, M. Morse, P.A. Ascierto, J. Lopez-Martin, P. Brossart, K.S. Rohrberg, B. Mellado, S. Li, C. Baudelet, K. Unsal-Kacmaz, M.K. Callahan, J.E. Rosenberg
Journal: Annals of Oncology (2020)
1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
Authors: E. Felip, F.L. Lim, M. Johnson, M. O'Brien, F. Barlesi, J. Mazieres, B. Solomon, V. Moreno, V. Boni, A. Swalduz, S. Goldberg, B. Keam, S. Allen, H-J. Helms, C. Shemesh, J. Pintoffl, N. Al-Sakaff, L. Bailey, P. Sayyed, B.C. Cho
Journal: Annals of Oncology (2020)
The GM-CSF–IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses
Authors: Isabelle C. Arnold, Mariela Artola-Boran, Alessandra Gurtner, Katrin Bertram, Michael Bauer, Ziva Frangez, Burkhard Becher, Manfred Kopf, Shida Yousefi, Hans-Uwe Simon, Alexandar Tzankov, Anne Müller
Journal: The Journal of Experimental Medicine (2020)

The depletion of eosinophils represents an efficient strategy to alleviate allergic asthma, but the consequences of prolonged eosinophil deficiency for human health remain poorly understood. We show here that the ablation of eosinophils severely compromises antitumor immunity in syngeneic and genetic models of colorectal cancer (CRC), which can be attributed to defective Th1 and CD8+ T cell responses. The specific loss of GM-CSF signaling or IRF5 expression in the eosinophil compartment phenocopies the loss of the entire lineage. GM-CSF activates IRF5 in vitro and in vivo and can be administered recombinantly to improve tumor immunity. IL-10 counterregulates IRF5 activation by GM-CSF. CRC patients whose tumors are infiltrated by large numbers of eosinophils also exhibit robust CD8 T cell infiltrates and have a better prognosis than patients with eosinophillow tumors. The combined results demonstrate a critical role of eosinophils in tumor control in CRC and introduce the GM-CSF–IRF5 axis as a critical driver of the antitumor activities of this versatile cell type.
Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial
Authors: Liselotte Boevé, Maarten C.C.M. Hulshof, Paul C.M.S. Verhagen, Jos W.R. Twisk, Wim P.J. Witjes, Peter de Vries, R. Jeroen A. van Moorselaar, George van Andel, André N. Vis
Journal: European Urology (2020)
433P A phase Ib/II clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancer
Authors: F. Wang, M-M. He, Y-C. Yao, Z-Q. Wang, Y. Jin, F-H. Wang, M-Z. Qiu, Z-D. Lv, D-S. Wang, H-Y. Luo, Y-H. Li, D-S. Zhang, R. Xu
Journal: Annals of Oncology (2020)
Mini Percutaneous Nephrolithotomy Is a Noninferior Modality to Standard Percutaneous Nephrolithotomy for the Management of 20–40 mm Renal Calculi: A Multicenter Randomized Controlled Trial
Authors: Guohua Zeng, Chao Cai, Xianzhong Duan, Xun Xu, Houping Mao, Xuedong Li, Yong Nie, Jianjun Xie, Jiongming Li, Jun Lu, Xiaofeng Zou, Jianfeng Mo, Chengyang Li, Jianzhong Li, Weiguo Wang, Yonggang Yu, Xiang Fei, Xianen Gu, Jianhui Chen, Xiangbo Kong, Jian Pang, Wei Zhu, Zhijian Zhao, Wenqi Wu, Hongling Sun, Yongda Liu, Jean de la Rosette
Journal: European Urology (2020)
1813MO Impact of systemic inflammation, intramuscular adipose tissue content, and EORTC-QLQ-CAX24 symptom scale on the prognosis of patients with advanced non-small-cell lung cancer
Authors: G. De Castro, W. das Neves Silva, A.P.D.S. Borges, V.C. Jardim, P.C.B.C. Brum, A. Fujita
Journal: Annals of Oncology (2020)
1693P Accurate triage may be efficacious in selecting patients who could safely continue anticancer therapy during SARS-CoV-2 pandemic
Authors: C. Gurizzan, R. Pedersini, C. Fornaro, C. Sardini, M. Zamparini, S. Monteverdi, V. Tovazzi, D. Cosentini, A. Dalla Volta, A. Baggi, A. Turla, P. Di Mauro, L. Lorini, M. Laganà, S. Bianchi, S. Intagliata, F. Consoli, E. Conti, P. Bossi, A. Berruti
Journal: Annals of Oncology (2020)
441P Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study
Authors: J.C. von Einem, V. Heinemann, D.P. Modest, A. Stahler, L. Miller-Phillips, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S-E. Al-Batran, C. Kahl, G. Seipelt, F. Kullmann, W. Scheithauer, A. Jung, T. Kirchner, S. Stintzing
Journal: Annals of Oncology (2020)
1363P Real-world treatment patterns of patients with locally advanced/metastatic EGFRm NSCLC in Belgium (REVEAL)
Authors: K. Cuppens, L. Lodewyckx, I. Demedts, L. Decoster, B. Colinet, K. Deschepper, A. Janssens, D. Galdermans, T. Pieters
Journal: Annals of Oncology (2020)
953P Sarcopenia as predictive factor of response to nivolumab in recurrent-metastatic head and neck (RM-SCCHN) cancer patients
Authors: F.M. Schipilliti, A. Pecchi, L. Trudu, M. Napolitano, A. Spallanzani, F. Valoriani, L. Reverberi, F. Prampolini, F. Martelli, R. Depenni, M. Dominici, F. Bertolini
Journal: Annals of Oncology (2020)
759P Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy
Authors: D. Castellano Gauna, E. Grande, M.A. Climent Duran, N. Lainez, I. Duran, C. Carrato, T. Lobato, E. Andrada, R. Gonzalez Gonzalez, L. Astudillo, S. Vazquez Estevez, B. Mellado Gonzalez, I. García Carbonero, M. Lázaro Quintela, M. Saez, E. Gonzalez Billalabeitia, M. Guix Arnau, A. Font, N. Malats, F. Real
Journal: Annals of Oncology (2020)
Clinical Outcomes of In-Hospital Cardiac Arrest in COVID-19
Authors: Shrinjaya B. Thapa, Tanya S. Kakar, Corey Mayer, Dilip Khanal
Journal: JAMA Internal Medicine (2020)

Because of the higher prevalence of dementia among those with lower socioeconomic status, the intergenerational effect of caregiving is particularly concerning for those already struggling to achieve equity.Existing programs that provide short-term, episodic support for caregivers (eg, the US Family Medical Leave Act and paid family leave) do not match the long-term, progressive care needs of those with dementia.
1846P Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head &amp; neck (H&amp;N) cancer
Authors: D. Osei-Fofie, G. Landers, J.A. Wetter, P. Kraus, S. Sukumaran, H. Mun, B. Stein, V.J. Bray, C.A. Connell, B. Framroze, J. Gelfand, A. Lategan, P. Song, M. Dimitriu, S. Sonis
Journal: Annals of Oncology (2020)
573P Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure
Authors: A. Hernando-Calvo, A. Valdivia, O. Saavedra Santa Gadea, I. Braña, R. Berché, I. Matos, M. Vieito, A.B. Azaro Pedrazzoli, G. Alonso Casal, V. Galvão, M. Diez Garcia, H. Verdaguer, C. Ortiz Velez, M. Gonzalez, I. Baraibar Argota, A. Callejo, E. Munoz Couselo, J. Tabernero, R. Dienstmann, E. Garralda
Journal: Annals of Oncology (2020)
1893P Hypersensitivity reaction to chemotherapy and monoclonal antibodies. Outcomes of 97 desensitisation in 24 patients: A single-hospital experience
Authors: V. Zenzola, M. Seoane, J. Ruiz Hornillos, A. Henriquez-Santana, S. Blanco Bermejo, C. Ortega, C. Garzón
Journal: Annals of Oncology (2020)
991P Sintilimab plus IBI305 as first-line treatment for advanced hepatocellular carcinoma
Authors: F. Jia, Z. Ren, J. Xu, G. Shao, G. Dai, B. Liu, A. Xu, Y. Yang, Y. Wang, H. Zhou, M. Chen
Journal: Annals of Oncology (2020)

A phase II/III study, is being conducted to evaluate the efficacy and safety of sintilimab, a PD-1 blockade, plus IBI305, a bevacizumab biosimilar, comparing with sorafenib as first-line treatment for advanced HCC (NCT03794440). In phase II, the safety run-in part, adults with advanced or metastatic HCC (histologically diagnosed or clinical diagnosed for cirrhosis per AASLD guideline) were enrolled to receive sintilimab (200 mg IV Q3W) plus IBI305 (15 mg/kg IV Q3W). The primary endpoint is safety profile. In phase III part, following the same inclusion and exclusion criteria, it is planned to enroll 546 pts. Eligible patients were randomized (2:1) to receive sintilimab (200 mg IV Q3W) plus IBI305 (15 mg/kg IV Q3W) or sorafenib (400 mg orally, BID). The primary endpoints are OS and PFS by IRC per RECIST 1.1. The phase III part is ongoing and patient enrollment has completed. We reported the results from phase II part herein. As of Feb 3rd, 2020, 24 pts were enrolled in phase II part. With a median treatment duration of 9.2 months, 18 (75%) pts experienced TRAEs. Grade ≥ 3 TRAEs were reported in 6 (25%) pts, including proteinuria (3 [12.5%]), hepatic function abnormal (2 [8.3%]), hyperthyroidism (1 [4.2%]) and immune-mediated hepatitis (1 [4.2%]). No TRAE resulted in treatment discontinuation and death. With a median follow-up of 9.0 months, the median OS was not reached and the 6-month OS rate was 87.1%. The median PFS was 8.4 months (95% CI, 5.6, not reached) and the 6-month PFS rate was 60.9%. The ORR assessed by the investigator per RECIST 1.1 was 25.0% and DCR was 83.3%. The data from phase II part showed acceptable safety profile and promising efficacy of sintilimab plus IBI305 as first-line treatment for advanced HCC.
809MO Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint)
Authors: D. Cella, M. Bookman, K. Dahl Steffensen, R.L. Coleman, M. Dinh, N. Khandelwal, K. Benjamin, R. Kamalakar, D. Sullivan, L. Floden, S. Hudgens
Journal: Annals of Oncology (2020)
1884P Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients
Authors: M. Metz, D. Semsek, G. Rogmans, U. Hutzschenreuter, T. Fietz, J. Harde, S. Zacharias, C. Hielscher, A. Lorenz, M-O. Zahn, D. Guth, S. Grebhardt, C.D. Fichter, K. Potthoff
Journal: Annals of Oncology (2020)
Identification and Market Removal of Risky Medical Devices
Authors: Madris Tomes
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres
Authors: L. Aguinaga, R. Ursu, J. Legoff, C. Delauguerre, O. Nguyen, S. Harel, B. Royer, M. sebert, M. Jachiet, C. Lebbé, C. Bonnet, P. Brice, P. Fenaux, B. Plaud, T. Aparicio
Journal: Annals of Oncology (2020)
518P Treatment outcome and prognostic factors after chemoradiotherapy for anal cancer
Authors: K.S. Slørdahl, J-A. Olsen, D. Klotz, E. Skovlund, C. Undseth, H.L. Abildgaard, M. Brændengen, A. Nesbakken, S.G. Larsen, B. Hanekamp, L. Holmboe, R. Tvedt, E. Malinen, S. Kaasa, M.G. Guren
Journal: Annals of Oncology (2020)
The Impact of COVID-19 on CGM Use in the Hospital
Authors: Nicole Ehrhardt, Irl B. Hirsch
Journal: Diabetes Care (2020)

In 1995 the movie Outbreak was released, and we shivered but were amused. The fictional virus “Motaba” was soon replaced by the very real H1N1, severe acute respiratory syndrome coronavirus (SARS-CoV, which causes SARS), and Ebola. Fortunately, the overall devastation of these potential pandemics, with the concern of deaths in the thousands or millions, never materialized. However, now the world is faced with SARS-CoV-2, the virus known to cause coronavirus disease 2019 (COVID-19), and the 2020 “Outbreak” movie is not fictional. This virus is real, and we are racing to find ways to save lives from this deadly disease while protecting the health and well-being of frontline health care workers.

There is now a strong body of evidence that diabetes, established cardiovascular disease, and other metabolic risk factors (particularly visceral fat accumulation) are associated with increased risk of need for mechanical ventilation, acute kidney injury, and mortality (1–4). Hyperglycemia during hospitalization for COVID-19 has also been established as a poor prognostic indicator (4,5). Some studies report that those with previously poorly controlled diabetes tend to have higher morbidity and mortality (4). However, another recent study found that previous insulin use, not HbA1c, was a predictor of mortality (6). More recently reported was that COVID-19 survivors had lower mean glucose during hospitalization than nonsurvivors (7). This finding brings some of the old controversy about glycemic management in the hospital to light, raising the question of whether lowering glycemic goals may help mitigate the acute on top of chronic inflammatory response and improve outcomes.

A report in 2001 on critically ill surgical patients gained wide attention (8). Intensive insulin therapy in the intensive care unit (ICU) improved morbidity and mortality, and much of the diabetes world extrapolated these findings to all patients in all hospitals. Unfortunately, …
FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma
Authors: Ying Wang, Zhaojie Lyu, Yanru Qin, Xia Wang, Liangzhan Sun, Yu Zhang, Lanqi Gong, Shayi Wu, Shuo Han, Ying Tang, Yongxu Jia, Dora Lai-Wan Kwong, NgarWoon Kam, Xin-Yuan Guan
Journal: Theranostics (2020)

Objective: The transcription factor forkhead box protein O1 (FOXO1) is critical for regulating cytokine and chemokine secretion. However, its function in the tumor microenvironment (TME) remains largely unexplored. In this study, we characterized the prognostic value of FOXO1 and the interaction between tumor-derived FOXO1 and M2 macrophages in esophageal squamous cell carcinoma (ESCC). Methods: FOXO1 expression and macrophage infiltration in clinical samples and mouse models were quantified using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry staining. Western blotting, qRT-PCR, and enzyme-linked immunosorbent assay were used to evaluate chemokine ligand 20 (CCL20) and colony stimulating factor 1 (CSF-1) expression in FOXO1(+) and FOXO1(-) tumor cells. Macrophage phenotypes were determined using qRT-PCR, flow cytometry, and RNA sequencing. Transcriptional activity was measured using chromatin immunoprecipitation (ChIP)-qPCR. Tumor viability was investigated using XTT proliferation and foci formation assays. Results: FOXO1 upregulation in tumor tissues was found to drive the polarization of M0 macrophages and infiltration of M2 macrophages into the TME, resulting in worse prognosis in ESCC patients. CSF-1, a vital factor inducing M0-to-M2 polarization, was upregulated via a FOXO1-mediated mechanism. RNA sequencing results corroborated that the FOXO1-induced macrophages exhibited similar molecular signatures to the IL4-stimulated M2 macrophages. The transwell assays showed that FOXO1 promoted the migration of M2 macrophages via CCL20 secretion, which could be inhibited using an anti-CCL20 antibody. FOXO1(+) tumor-induced M2 macrophages promoted tumor proliferation via the FAK-PI3K-AKT pathway and the PI3K inhibitor could effectively impede the oncogenical process. Conclusions: FOXO1 facilitated M0-to-M2 polarization and the recruitment of M2 macrophages in the TME via the transcriptional modulation of CCL20 and CSF-1. Our data deciphered the FOXO1-dependent mechanism in M2 macrophage infiltration in the TME of ESCC, which has implications for the development of novel prognostic and therapeutic targets to optimize the current treatment against ESCC.
Chromothripsis in Human Breast Cancer
Authors: Michiel Bolkestein, John K.L. Wong, Verena Thewes, Verena Körber, Mario Hlevnjak, Shaymaa Elgaafary, Markus Schulze, Felix K.F. Kommoss, Hans-Peter Sinn, Tobias Anzeneder, Steffen Hirsch, Frauke Devens, Petra Schröter, Thomas Höfer, Andreas Schneeweiss, Peter Lichter, Marc Zapatka, Aurélie Ernst
Journal: Cancer Research (2020)

Chromothripsis is a form of genome instability by which a presumably single catastrophic event generates extensive genomic rearrangements of one or a few chromosomes. Widely assumed to be an early event in tumor development, this phenomenon plays a prominent role in tumor onset. In this study, an analysis of chromothripsis in 252 human breast cancers from two patient cohorts (149 metastatic breast cancers, 63 untreated primary tumors, 29 local relapses, and 11 longitudinal pairs) using whole-genome and whole-exome sequencing reveals that chromothripsis affects a substantial proportion of human breast cancers, with a prevalence over 60% in a cohort of metastatic cases and 25% in a cohort comprising predominantly luminal breast cancers. In the vast majority of cases, multiple chromosomes per tumor were affected, with most chromothriptic events on chromosomes 11 and 17 including, among other significantly altered drivers, CCND1, ERBB2, CDK12, and BRCA1. Importantly, chromothripsis generated recurrent fusions that drove tumor development. Chromothripsis-related rearrangements were linked with univocal mutational signatures, with clusters of point mutations due to kataegis in close proximity to the genomic breakpoints and with the activation of specific signaling pathways. Analyzing the temporal order of events in tumors with and without chromothripsis as well as longitudinal analysis of chromothriptic patterns in tumor pairs offered important insights into the role of chromothriptic chromosomes in tumor evolution. SIGNIFICANCE: These findings identify chromothripsis as a major driving event in human breast cancer.
Long-term outcomes of therapist-guided Internet-delivered cognitive behavior therapy for pediatric obsessive-compulsive disorder
Authors: Fabian Lenhard, Erik Andersson, David Mataix-Cols, Christian Rück, Kristina Aspvall, Eva Serlachius
Journal: npj Digital Medicine (2020)

Cognitive behavior therapy (CBT) is the recommended first-line intervention for children and adolescents with obsessive-compulsive disorder (OCD), but is not broadly accessible. Internet-delivered CBT (ICBT) with minimal therapist support is efficacious and cost-effective, at least in the short term. Whether the therapeutic gains of ICBT for OCD are sustained in the long run is unknown. In this study, 61 adolescents with OCD who participated in a randomized trial of ICBT were followed-up 3 and 12 months after treatment. The proportion of treatment responders and remitters remained stable from post-treatment to 3-month follow-up and increased significantly from 3-month to 12-month follow-up. This study suggests that the gains of ICBT for youth with OCD are not only maintained long-term, but that further improvements continue to occur during follow-up.